Document is current
Any future updates will be listed below
-
Authors
Higdon, Claudine
Welge, Jeffrey A.
Crimmins, Nancy A.
Klein, Christina C.
Fornari, Victor M.
Sorter, Michael T.
Blom, Thomas J.
Kurtz, Brian P.
Correll, Christoph U.
DelBello, Melissa P.
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02515773 at ClinicalTrials.govDocuments that mention this clinical trial
Metabolic syndrome in youth with bipolar spectrum disorders treated with second-generation antipsychotics: baseline results from the community-based pragmatic MOBILITY Trial
https://doi.org/10.1007/s00787-025-02680-2
-
Funding
Funding for this research was provided by:
Patient Centered Outcome Research Institute (PCS-1406-19276, PCS-1406-19276, PCS-1406-19276, PCS-1406-19276, PCS-1406-19276, PCS-1406-19276, PCS-1406-19276, PCS-1406-19276, PCS-1406-19276, PCS-1406-19276)
- License Information
-
More Information
Article History
Received: 18 July 2024
Accepted: 19 February 2025
First Online: 11 April 2025
Declarations
:
: All authors received salary support from Patient Centered Outcome Research Institute (PCORI). Dr. Brian P. Kurtz has been a consultant to PCORI. Dr. Christoph U. Correll has been a consultant and/or advisor to or has received honoraria from: AbbVie, Acadia, Adock Ingram, Alkermes, Allergan, Angelini, Aristo, Biogen, Boehringer-Ingelheim, Bristol-Meyers Squibb, Cardio Diagnostics, Cerevel, CNX Therapeutics, Compass Pathways, Darnitsa, Delpor, Denovo, Gedeon Richter, Hikma, Holmusk, IntraCellular Therapies, Jamjoom Pharma, Janssen/J&J, Karuna, LB Pharma, Lundbeck, MedInCell, Merck, Mindpax, Mitsubishi Tanabe Pharma, Maplight, Mylan, Neumora Therapeutics, Neurocrine, Neurelis, Newron, Noven, Novo Nordisk, Otsuka, PPD Biotech, Recordati, Relmada, Reviva, Rovi, Sage, Saladax, Seqirus, SK Life Science, Sumitomo Pharma America, Sunovion, Sun Pharma, Supernus, Tabuk, Takeda, Teva, Tolmar, Vertex, Viatris and Xenon Pharmaceuticals. He provided expert testimony for Janssen and Otsuka. He served on a Data Safety Monitoring Board for Compass Pathways, Denovo, Lundbeck, Relmada, Reviva, Rovi, Supernus, and Teva. He has received grant support from Janssen and Takeda. He received royalties from UpToDate and is also a stock option holder of Cardio Diagnostics, Kuleon Biosciences, LB Pharma, Mindpax, and Quantic. Dr. Melissa P. DelBello has received research support from: Allergan, Alkermes, Janssen, Johnson and Johnson, Lundbeck, Myriad, NIMH, Otsuka,, Pfizer, Shire, and Sunovion. She has been a consultant and/or advisor to or has received honoraria from Alkermes, CMEology, Johnson and Johnson, Medscape, Myriad, and Sage.
